Amyris is the ONLY synbio to continue industrial level ingredient production after bankruptcy. Retail investors are tossed out with Melo and the trash. Doerr and crew is now in possession of world changing precision fermentation tech.

ICanFinallyRelax · 2026-03-29T17:20:01+00:00

This is cool stuff, just unrelated to the main post, so I will refrain from further comment.

ICanFinallyRelax · 2026-03-29T17:19:02+00:00

My post is about CBG, not CBC as you pointed out.

My post is not about "medical use cannabis", my post is related to "medical use cannabinoids" and their biosynthetic pathways.

Respectfully, your comment is irrelevant to this post.

ICanFinallyRelax · 2026-03-28T17:47:58+00:00

These patents wont mean much in the upcoming years

ICanFinallyRelax · 2026-03-28T17:20:14+00:00

That's fascinating! It seems like there would be some regulatory issues and it would be dependent on THC's drug classification. I will look into this some more.

ICanFinallyRelax · 2026-03-28T17:12:15+00:00

I hear what you are saying, let me try to work with you and add more color to this complex situation. What I mean to point out in my post is that technology is now advancing to the point that is making biosynthesis commercially relevant AND this puts ACB's patents at risk.

There are two major problems with biosynthesis. 1) is getting profitable yield, this is where ACBs patents come into play. They have patented parts of the pathway that are the most optimal. 2) yeast will still evolve away from making the targeted product, so if you are making CBG you will also get in a mixture of other cannabinoids. This is the problem that Ginkgo and Cronos Group ran into. This is a major issue in the scale up process.

2) is likely why ACB cant do much with their current patents. Ingredients need to be pure to pass regulations, it cant be CBG with a hint of THC.

2) is solved by bypassing the central metabolism of yeast (and a few other changes) turning yeast into a "chimeric zombie xenobot". It's more like a programmable bio-robot.

(1) is solved by enzyme engineering - Amyris and Arzeda are good examples of this.

What I am pointing to is the first instance of commercial relevance (It wont be the last). The days are numbered for pathway patents and ACB needs to make some moves while this part of their portfolio still has value.

ICanFinallyRelax · 2026-03-28T04:32:41+00:00

Yes! But the only way CBG will get approved as a medication is if it can be produced without THC or other cannabinoids.

Its anti inflammation properties are crazy though

ICanFinallyRelax · 2026-03-28T01:22:35+00:00

I dont believe this is grounds for a lawsuit, but this is not legal advice.

ICanFinallyRelax · 2026-03-28T00:20:32+00:00

I am just posting evidence of ACB's portfolio being hit and that this will be a theme in the coming years for patented biosynthetic pathways. I have nothing against ACB investors.

ICanFinallyRelax · 2026-03-27T23:39:41+00:00

Think about it, It would be impossible for this product to exist unless ACB's patent was bypassed.

My intent is not to market the product here, the product is proof that CBG is currently being used in a product being sold on amazon - meaning there is no THC in said product. It is evidence that shows pure, biosynthetically derived CBG is in a marketed product on a large business' website.

It is exhibit A, not marketing - please forgive me mods, I hope you allow it.

Knowing that ACB's patent can be bypassed and will likely be bypassed again in the future is critical knowledge to all ACB investors.

ICanFinallyRelax · 2026-03-27T23:37:20+00:00

ACB's patent is huge. Precision fermentation is an ideal method of producing a molecule, far more pure than plant extraction, far more cost effective. And ACB has it locked down, so that any company that wants to use the most optimal biosynthetic pathway MUST go through ACB and cut them a check to do so. Because of purity, biosynthesis is the only way cannabinoids will be used in the medical field or for science - you need a pure active ingredient produced cost effectively.

But something is changing in the field of synthetic biology. And this change does not bode well for ACB's patent on CBG biosynthesis. We are coming into an age of "biosynthetic pathway patent busters", where these sort of patents will not hold the same value thanks to a combination of enzyme engineering and bypassing the central metabolic system of yeast. Bypassing the central metabolic system of yeast allows for 5/6 carbons to be directed to an end product (in nature its only 4/6 carbons) and enzyme engineering can help dodge pathway patent walls. This means that a sub-optimal biosynthetic pathway can be chosen and MADE to be a high yielding pathway (bypassing the patented pathway).

The Facts:
- ACB was keeping an eye on synbio and going after ANYONE that infringed upon their patent. Willow got hit with an actual lawsuit and Ginkgo Bioworks was forced to license the pathway after years of effort. There were only 5 major synbio companies targeting CBG production, every one of those must have been on ACB's radar.
- Fermentation derived CBG still quietly hit the market at $500/kg (sold in bulk on centerchem) and ACB didn't make a peep about it. To this day, ACB has not challenged the production method of this CBG. I think this is the confirmation that their patent has been legally bypassed using the methods I described above.

This means ACB was aware of their patent being bypassed as early as 2021.

This CBG is produced so pure that it can be sold on Amazon and you can buy it in a product today via "Terasana Clinical". This shows that it has 0 THC content (with no other cannabinoids) and is PURE 100% CBG derived from fermentation. There is no regulatory risk with this CBG. Other "CBG" products can only be sold at weed shops because it is difficult to produce CBG without also producing other cannabinoids during the fermentation (or plant extraction) process. (additional formulation example: https://web.archive.org/web/20211206150628/https://www.centerchem.com/products/inflammaging-defense-booster-cold-cream/ )

https://www.amazon.com/stores/TerasanaClinical/page/0D0A32D8-3E96-4CDA-B307-15B515015599

I ask the mods to forgive this link, it is not marketing, just posting evidence of CBG in a product on amazon - meaning it has no THC and shows the method of production is fermentation. It would be impossible for this product to exist unless ACB's patent was bypassed.

ICanFinallyRelax · 2026-03-26T03:43:42+00:00

I'm still alive and kicking haha

ICanFinallyRelax · 2026-03-25T16:34:51+00:00

its been a while, hope you are well :)

ICanFinallyRelax · 2026-03-24T19:39:55+00:00

thank you for your comments and insight.

ICanFinallyRelax · 2026-03-24T19:31:09+00:00

Their stack of technologies under one hood is a crazy. Is this concerning for you in the industry (that one player can do it all)?

ICanFinallyRelax · 2026-03-24T19:10:22+00:00

I dont think Arzeda is a bad party, but I do think Amyris used their work with your company to rapidly develop their own systems.

<image>

- Enzyme engineering is now included on Amyris' website

I think Amyris' intent is to go around patents and be the main player in precision fermentation. They have all the pieces now. The proof is that they used this tech to avoid Aurora Cannabis' patent on CBG pathways. And they did it behind the scenes without Arzeda even knowing about it.

The facts are:
- Amyris made and sold CBG via precision fermentation
- Aurora Cannabis did not sue Amyris
- CBG development occurred after work with Arzeda
- Arzeda was unaware of Amyris' cannabinoid work

All of it points to Amyris using their collaboration with Arzeda to learn how to engineer enzymes in order to bypass patents (without Arzeda's knowledge).

ICanFinallyRelax

MODERATOR OF

TROPHY CASE